VEGFA and neoplasm: Blood clearance followed a biphasic pattern, with a biological half-life of 8–9 days, supporting the feasibility of HuMV833 for VEGF imaging and therapeutic monitoring; however, no clear relationship was observed between plasma pharmacokinetics and drug clearance from the tumor over 24–48 h.